Analyzing Sanuwave Health (SNWV) & Its Competitors

Valuation and Earnings

This table compares Sanuwave Health and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Sanuwave Health	$32.63 million	-$31.37 million	-7.24
Sanuwave Health Competitors	$2.76 billion	$240.98 million	3.88

Sanuwave Health’s competitors have higher revenue and earnings than Sanuwave Health. Sanuwave Health is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

42.5% of Sanuwave Health shares are held by institutional investors. Comparatively, 44.3% of shares of all “MED PRODUCTS” companies are held by institutional investors. 36.6% of Sanuwave Health shares are held by company insiders. Comparatively, 12.6% of shares of all “MED PRODUCTS” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Sanuwave Health has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Sanuwave Health’s competitors have a beta of 0.69, indicating that their average stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Sanuwave Health and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Sanuwave Health	-89.86%	N/A	-145.76%
Sanuwave Health Competitors	-73.31%	-48.52%	-12.83%

Summary

Sanuwave Health competitors beat Sanuwave Health on 6 of the 9 factors compared.

About Sanuwave Health

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.